ANI Pharmaceuticals, Inc. (ANIP) News
Filter ANIP News Items
ANIP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANIP News Highlights
- ANIP's 30 day story count now stands at 2.
- Over the past 15 days, the trend for ANIP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ANIP are NOV.
Latest ANIP News From Around the Web
Below are the latest news stories about ANI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ANIP as an investment opportunity.
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 59% gainANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) shareholders have seen the share price descend 23% over the month. But that... |
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceBAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows: Date: Tuesday, November 28, 2023 Time:1:00pm – 1:25pm ET Webcast: Click Here To schedule a 1x1 meeting with the Company, please contact [email protected]. The live and archived webcast will be accessible from the Company’s web |
A Boring Biopharma Can Be a Good BetInvestors have finally seen some long awaited and much needed breadth within the market rally in recent trading sessions. This strategy provides downside protection of approximately 14% during the five-month option duration. |
Insider Sell Alert: SVP, CHIEF HR OFFICER Krista Davis Sells Shares of ANI Pharmaceuticals IncANI Pharmaceuticals Inc (NASDAQ:ANIP) has recently witnessed an insider sell that has caught the attention of investors and market analysts. |
Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock Price Struggling As A Result Of Its Mixed Financials?With its stock down 20% over the past week, it is easy to disregard ANI Pharmaceuticals (NASDAQ:ANIP). It is possible... |
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call TranscriptANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call Transcript November 8, 2023 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.27, expectations were $0.76. Operator: Good day, everyone, and welcome to the ANI Pharmaceuticals, Inc. Third Quarter 2023 Earnings Results Call. At this time, all participants are in a listen-only mode. Later, you will […] |
ANI Pharmaceuticals Inc (ANIP) Reports Record Q3 2023 Results; Raises Full-Year GuidanceRobust Revenue Growth and Strong Rare Disease Asset Performance Drive Upward Revision in 2023 Projections |
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 GuidanceThird Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly adjusted non-GAAP EBITDA of $36.5 million representing year-over-year growth of 98.3%; adjusted non-GAAP diluted earnings per share of $1.27 -- -- Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 8 |
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |